Advanced Enzymes reported mixed results for Q3 FY26, with revenue at INR 1,719 million, a 2% year-over-year increase. Human Healthcare segment experienced a 6% decline, while Animal Healthcare rose 22%. The company remains optimistic and focuses on operational excellence to achieve full-year guidance. They are also closely monitoring the impact of U.S. tariffs and are exploring new opportunities in various enzyme segments. EBITDA stood at INR 494 million.
Financial Performance Overview
Advanced Enzymes’ Q3 FY26 revenue reached INR 1,719 million, reflecting a 2% year-over-year growth but a 7% decline compared to the previous quarter. Year-to-date revenue increased by 15%. EBITDA for the quarter was INR 494 million, with a margin of 29%.
Segment Performance
Human Healthcare: Revenue stood at INR 962 million, a 6% year-over-year decline, contributing 56% to total revenue. Lower sales in Pharma, API, and Nutrition impacted this segment.
Animal Healthcare: Revenue rose to INR 241 million, a 22% year-over-year increase, accounting for 14% of total revenue.
Bioprocessing: Recorded 13% year-over-year growth, driven by robust food business performance.
Specialized Manufacturing: Remained flat year-over-year, representing 9% of overall revenue.
Subsidiary Performance
JC Biotech: Quarterly revenue was INR 159 million, with an EBITDA of INR 7 million and a net loss of INR 4 million.
Evoxx: Revenue stood at INR 87 million, with an EBITDA of INR 22 million and a net profit of INR 15 million.
Strategic Focus and Outlook
The company is focused on enhancing resilience, adapting to market dynamics, and exploring new opportunities in enzyme segments. They are monitoring the impact of U.S. tariffs and aiming for growth in the U.S. markets.
R&D and Expansion
R&D expenditure for Q3 was INR 77 million on a standalone basis. The company is planning to commission a new R&D center by the end of Q2 FY27, focusing on strain development, protein engineering, and fermentation.
Source: BSE
